Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06405828 | Enhancing Access to Supportive Services for Women of Color With Metastatic Breast Cancer(ACCESS) | recruiting | N/A | 67 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT06749210 | DAANCE FOR CHEMOTHERAPY-INDUCED NEUROPATHY(DAANCE) | recruiting | Phase 2 | 140 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Nov 5, 2025 |
| clinicaltrials |
| NCT05902988 | A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | recruiting | Phase 1 / Phase 2 | 200 | Volastra Therapeutics, Inc.INDUSTRY | 1 | Nov 4, 2025 | clinicaltrials |
| NCT06574022 | Post-mastectomy Recovery: Comparing Preoperative PECS-II Blocks With Intraoperative Pectoral Blocks | recruiting | Phase 4 | 100 | University of CincinnatiOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT03643861 | RAD 1802: Pilot Trial of Five Fraction Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI) | recruiting | N/A | 40 | University of Alabama at BirminghamOTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT06960720 | Lifting More Than Weights: Resistance Exercise Program Across Socioeconomic Groups for Cancer-Related Fatigue Management | recruiting | N/A | 60 | West Virginia UniversityOTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT07016399 | Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC | recruiting | Phase 2 | 51 | Vandana AbramsonOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT00291096 | High Risk Breast Clinic: Protocol for Women at Increased Risk for Developing Breast Cancer | recruiting | — | 3,000 | Carol Fabian, MDOTHER | 1 | Oct 29, 2025 | clinicaltrials |
| NCT06954831 | Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer | recruiting | Phase 2 | 82 | City of Hope Medical CenterOTHER | 1 | Oct 29, 2025 | clinicaltrials |
| NCT03452774 | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | recruiting | — | 50,000 | Massive Bio, Inc.INDUSTRY | 2 | Oct 28, 2025 | clinicaltrials |
| NCT07054723 | Surviving Daily Life(GOCE) | recruiting | — | 30 | Thomas Jefferson UniversityOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT00898131 | Collecting Tissue Samples for Future Research From Women Undergoing Surgery for Breast Cancer | recruiting | — | 10,000 | Northwestern UniversityOTHER | 1 | Oct 20, 2025 | clinicaltrials |
| NCT06052488 | Strength After Breast Cancer(SABC) | recruiting | N/A | 40 | MGH Institute of Health ProfessionsOTHER | 1 | Oct 20, 2025 | clinicaltrials |
| NCT05620329 | UNC Pleural Fluid Registry | recruiting | — | 9,999 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Oct 16, 2025 | clinicaltrials |
| NCT00823654 | Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations | recruiting | — | 609 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT05561842 | Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria (Mobile Health: Technology and Outcomes in Low and Middle-Income Countries) | recruiting | — | 900 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Oct 14, 2025 | clinicaltrials |
| NCT06361940 | Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer(MAPPER) | recruiting | Phase 2 | 100 | Medical College of WisconsinOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT06784193 | Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 180 | Olema Pharmaceuticals, Inc.INDUSTRY | 2 | Oct 10, 2025 | clinicaltrials |
| NCT06507930 | The COMPASSION Study | recruiting | N/A | 200 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 9, 2025 | clinicaltrials |
| NCT07214883 | UCF MammoChat: Image Repository | recruiting | — | 20,000 | University of Central FloridaOTHER | 1 | Oct 9, 2025 | clinicaltrials |
| NCT03418961 | S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity | recruiting | Phase 3 | 491 | SWOG Cancer Research NetworkNETWORK | 4 | Oct 8, 2025 | clinicaltrials |
| NCT06960291 | Sustainable Implementation of the EXCEL Exercise Oncology Program Across Canada(EXCEL) | recruiting | N/A | 740 | University of CalgaryOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT06260033 | Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer | recruiting | Phase 2 | 18 | City of Hope Medical CenterOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT06433349 | A Multi-center Investigation of Family Health. | recruiting | — | 240 | Odense University HospitalOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT06529614 | An In-situ Detection for MicroRNA | recruiting | — | 100 | Tongji HospitalOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT05466786 | Distribution of the Homologous Recombination-related (HRR) Genesmutationsand HRD in Breast Cancer | recruiting | — | 255 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT05984888 | Pilot Study of a MIND Diet Intervention in Women Undergoing Active Treatment for Breast Cancer(MIND-BC) | recruiting | N/A | 43 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT06957535 | Community-led Navigation to Address Disparities in Mammography Among Native American Women | recruiting | N/A | 200 | Johns Hopkins Bloomberg School of Public HealthOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT07166042 | Guided Meditation During Radiation Therapy for Breast and Gynecological Malignancies(Med-RT BG) | recruiting | Phase 3 | 34 | University of UtahOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT00722228 | Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors | recruiting | Phase 1 / Phase 2 | 50 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05296564 | Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers | recruiting | Phase 1 / Phase 2 | 3 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT04914663 | All-extremity Exercise During Breast Cancer Chemotherapy | recruiting | N/A | 68 | University of FloridaOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT05522959 | Cardio-Oncology Rehabilitation Exercise(CORE) | recruiting | — | 100 | University of TorontoOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT06178159 | DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer | recruiting | Phase 2 | 40 | RemeGen Co., Ltd.INDUSTRY | 1 | Oct 1, 2025 | clinicaltrials |
| NCT07081555 | A First-in-Human Phase 1 Safety and Biodistribution of [177Lu]Lu-ABY-271 in Subjects With HER2-positive Metastatic Breast Cancer | recruiting | Phase 1 | 21 | AffibodyINDUSTRY | 1 | Oct 1, 2025 | clinicaltrials |
| NCT07190443 | Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)(AURA) | recruiting | Phase 3 | 290 | Japanese Foundation for Cancer ResearchOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT06042894 | A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer | recruiting | Phase 2 | 58 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05760612 | Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab | recruiting | Phase 3 | 300 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT05866432 | Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases(TUXEDO-2) | recruiting | Phase 2 | 20 | Medical University of ViennaOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT06335069 | 18F-FDG Versus 68Ga-FAPI-46 as PET Tracer in ER-positive Breast Cancer. | recruiting | Phase 2 | 20 | Maastricht University Medical CenterOTHER | 1 | Sep 24, 2025 | clinicaltrials |
| NCT06708910 | AI-based pCR Assessment/Prediction in HER2-Positive BC Using PET/MRI | recruiting | — | 460 | Heinrich-Heine University, DuesseldorfOTHER | 1 | Sep 24, 2025 | clinicaltrials |
| NCT02893761 | Bergonie Institute Breast Cancer Database | recruiting | — | 30,000 | Institut BergoniéOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT05381038 | Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI | recruiting | Phase 1 / Phase 2 | 10 | National University Hospital, SingaporeOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT06087120 | Predicting BReast cAncer Response to neoadjuVant Therapy by ctDNA Assessment(BRAVA) | recruiting | — | 125 | Gene SolutionsINDUSTRY | 2 | Sep 23, 2025 | clinicaltrials |
| NCT06383026 | Individuals on Hormone Therapy Breast Cancer Screening Pilot | recruiting | — | 130 | Medical College of WisconsinOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT06732323 | A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer | recruiting | Phase 3 | 504 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
| NCT04069884 | RecurIndex Guided Avoidance of Regional Nodal Irradiation for Node Positive Breast Cancer(RIGAIN) | recruiting | N/A | 540 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT05184582 | Physical Exercise During Preoperative Chemotherapy for Breast Cancer(Neo-ACT) | recruiting | N/A | 712 | Karolinska InstitutetOTHER | 4 | Sep 22, 2025 | clinicaltrials |
| NCT06491680 | Cardiotoxicity in Breast Cancer Patients | recruiting | Phase 4 | 40 | Helwan UniversityOTHER | 1 | Sep 22, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Nov 5, 2025source: clinicaltrials